- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01476345
A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants
Bioequivalence Study Comparing the Pharmacokinetics and Pharmacodynamics of LY2963016 With Insulin Glargine in Healthy Volunteers
The purposes of this study are to determine the pharmacokinetics and pharmacodynamics of LY2963016 compared to those of basal insulin. The study will also gather information on the safety and tolerability of LY2963016 in healthy participants.
Each study period will be approximately 8.5 days (1.5 days for treatment and 7 day washout period). There are 4 study periods.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Bloemfontein, South Africa, 9301
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
are overtly healthy males or females, as determined by medical history and physical examination
- male participants: agree to use a reliable method of birth control during the study.
- female participants of child-bearing potential must test negative for pregnancy at the time of enrollment and agree to either abstain from sexual activity or to use a medically accepted means of contraception when engaging in sexual intercourse throughout the study, or female participants not of child-bearing potential due to surgical sterilization or menopause
- have a body weight of at least 55 kilograms (kg), and body mass index (BMI) of 18.5 to 32.0 kilograms/square meter (kg/m²)
- have clinical laboratory test results within normal reference range for the population
- have venous access sufficient to allow for blood sampling
- are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
- have given written informed consent
- participants should have a normal oral glucose tolerance test
Exclusion Criteria:
- are currently enrolled in, have completed or discontinued within the last 30 days from, a clinical trial involving an investigational product other than the investigational product used in this study; or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
- have known allergies to heparin, insulin glargine, related compounds or any components of the formulation
- are persons who have previously received the investigational product in this study, have completed or withdrawn from this study or any other study investigating LY2963016
- have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
- have an abnormal blood pressure as determined by the investigator
- have a significant history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, haematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication
- show evidence of significant active neuropsychiatric disease
- regularly use known drugs of abuse and/or show positive findings on urinary drug screening
- show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
- show evidence of hepatitis C and/or positive hepatitis C antibody
- show evidence of hepatitis B and/or positive hepatitis B surface antigen
- are women with a positive pregnancy test or women who are lactating
- intend to use over-the-counter or prescription medication
- have donated blood of more than 500 milliliters (mL) within the last 56 days before dosing of Period 1
- have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females), or are unwilling to stop alcohol consumption for 24 hours before dosing and throughout the duration of each study period
- smoke more than 10 cigarettes (or equivalent other tobacco products) per day
- have a fasting blood glucose > 5.5 millimoles/Liter (mmol/L) [>99 milligrams/deciliter (mg/dL)]at screening
- have a positive test for anti-LY2963016 or anti-glargine antibodies
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LY2963016
A single 0.5 units/kilogram (U/kg) dose of LY2963016 administered subcutaneously followed by minimum washout interval of 7 days.
|
Administered subcutaneously
|
Experimental: Lantus
A single 0.5 U/kg dose of Lantus administered subcutaneously followed by minimum washout interval of 7 days.
|
Administered subcutaneously
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to 24 Hours [AUC(0-24)] of LY2963016 and Lantus
Time Frame: 1 hour predose up to 24 hours postdose in all treatment periods
|
1 hour predose up to 24 hours postdose in all treatment periods
|
Pharmacokinetics: Maximum Plasma Concentration (Cmax) of LY2963016 and Lantus
Time Frame: 1 hour predose up to 24 hours postdose in all treatment periods
|
1 hour predose up to 24 hours postdose in all treatment periods
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Glucose Infusion Rate (Rmax)
Time Frame: 1 hour predose up to 24 hours postdose in all treatment periods
|
Rmax is the maximum infusion rate of glucose administered intravenously needed to maintain target blood glucose level and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure.
During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or Lantus by adjusting the exogenous glucose infusion rate.
Data presented were adjusted by the body weight.
|
1 hour predose up to 24 hours postdose in all treatment periods
|
Total Amount of Glucose Infused (Gtot) Over the Duration of Clamp Procedure
Time Frame: 1 hour predose up to 24 hours postdose in all treatment periods
|
Gtot is the total glucose infusion over the clamp duration and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure.
During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of LY2963016 or Lantus by adjusting the exogenous glucose infusion rate.
Data presented were adjusted by the body weight.
|
1 hour predose up to 24 hours postdose in all treatment periods
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13711
- I4L-MC-ABEA (Other Identifier: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
Meir Medical CenterCompletedDiabetes Mellitus Type 2 | Diabetes Mellitus, Non-insulin Dependant | Diabetes Mellitus, on Oral Hypoglycemic Treatment | Adult Type Diabetes MellitusIsrael
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownType2 Diabetes Mellitus | Type1 Diabetes MellitusUnited States
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Active, not recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type II | Diabetes Mellitus, Adult-Onset | Diabetes Mellitus, Non-Insulin-Dependent | Diabetes Mellitus, Noninsulin DependentUnited States
Clinical Trials on LY2963016
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedType 2 Diabetes MellitusIndia
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyBoehringer IngelheimCompletedDiabetes Mellitus, Type 2United States, Puerto Rico, Mexico, Korea, Republic of, Germany, Poland, Taiwan, Spain, Greece, France, Czech Republic, Hungary
-
Eli Lilly and CompanyWithdrawnType 2 Diabetes | Type 2 Diabetes Treated With InsulinUnited States
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedDiabetes MellitusSingapore
-
Eli Lilly and CompanyBoehringer IngelheimCompletedDiabetes Mellitus, Type 1Japan, United States, Greece, Belgium, Poland, Germany, Hungary, Mexico, Romania
-
Eli Lilly and CompanyCompletedDiabetes Mellitus, Type 1Germany
-
Eli Lilly and CompanyCompleted